|
**Overview**: ToRCH Panel IgM Extended**Introduction**: The ToRCH Panel IgM Extended is a diagnostic tool designed for extended congenital infection screening using serum samples. In India, extended IgM testing (Toxoplasma, Rubella, CMV, HSV-1/HSV-2) is essential for high-risk pregnancies with suspected acute infection, where HSV-1/HSV-2 differentiation guides neonatal risk assessment. High morbidity from under-testing in rural/low-SES pregnant women with symptoms or anomalies, limited extended serology labs, delayed antiviral or delivery planning leading to neonatal herpes or defects. Per obstetrics practices aligned with ICMR, FOGSI, and National Health Mission guidelines, the test employs immunoassay for Toxoplasma/Rubella/CMV/HSV-1/HSV-2 IgM over 1â€"2 days with high accuracy, valuable for comprehensive acute infection screening. This diagnostic falls under infectious disease screening and targets pregnant women with fever, rash, or fetal ultrasound findings, addressing accurate detection to guide avidity/PCR or intervention. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling detailed ToRCH IgM profiling and reducing congenital infection burden. Its serum-based approach ensures reliable multi-pathogen IgM assessment.**Other Names**: TORCH IgM Ext Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/immunology/clinical pathology, compliant with 2025 standards.**Historical Milestone**: Extended ToRCH IgM standard in high-risk antenatal; in India, expanding in tertiary care.**Purpose**: The test assesses 5 parameters including Toxoplasma IgM to guide extended congenital infection screening, detect acute exposure, inform intervention.**Test Parameters**: 1. Toxoplasma IgM, 2. Rubella IgM, 3. CMV IgM, 4. HSV-1 IgM, 5. HSV-2 IgM.**Pretest Condition**: No fasting required; patients should be pregnant with risk/symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve antibody integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on gestational age, lesions, anomalies.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of recent infection including neonatal herpes, benefits of extended screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IgM + HSV-2 suggests high neonatal risk, necessitating specialist input.**Specialist Consultation**: Fetal medicine specialists or obstetricians should be consulted for management.**Additional Supporting Tests**: IgG avidity, PCR on amniotic fluid for confirmation.**Test Limitations**: IgM false positives possible; comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, TORCH Studies India 2023. |
